{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:57:30Z","timestamp":1787324250573,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>Investigating the assessment of innovative serum indicators with elevated sensitivity and specificity is crucial for enhancing the early diagnosis and prognosis of HCC (Hepatocellular carcinoma). This study aimed to evaluate the efficacy of COPA (Coatomer Subunit Alpha) in diagnosing hepatocellular carcinoma and assessing the effectiveness of immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included two cohorts: a diagnostic cohort comprising 81 healthy controls, 118 patients with benign liver diseases, and 81 patients with pathologically confirmed HCC, and an immunotherapy cohort comprising 131 HCC patients treated with PD-1\/PD-L1 inhibitors. Serum COPA was measured by ELISA, while AFP and PIVKA-II were measured by electrochemiluminescence. Diagnostic performance and immunotherapy monitoring efficacy were then evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      COPA is upregulated in serum and HCC tumor samples. The ROC analysis indicated that the diagnostic efficacy of COPA (AUC = 0.911) surpassed that of traditional biomarkers. Importantly, COPA retained favorable diagnostic performance in both AFP-negative and PIVKA-II-negative HCC patients. Dynamic monitoring revealed that when comparing PIVKAII and AFP with imaging-based efficacy assessments, serum COPA changes demonstrated superior consistency pre- and post-immunotherapy (Kappa of COPA = 0.73,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). COPA expression was significantly elevated in HCC tissues compared with adjacent non-tumor tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study established that COPA outperforms AFP and PIVKAII in diagnostic and immunotherapeutic monitoring reliability, offering a novel technique for the precise diagnosis and treatment of hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1908605","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:21:00Z","timestamp":1787322060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum COPA for the diagnosis and immunotherapeutic monitoring of hepatocellular carcinoma: a retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ranliang","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueguo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12967-021-03218-1","article-title":"Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification","volume":"20","author":"Bao","year":"2022","journal-title":"J. Transl. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/gutjnl-2012-304037","article-title":"A disrupted RNA editing balance mediated by ADARs (Adenosine Deaminases that act on RNA) in human hepatocellular carcinoma","volume":"63","author":"Chan","year":"2014","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s42003-024-06520-y","article-title":"A-to-I RNA co-editing predicts clinical outcomes and is associated with immune cell infiltration in hepatocellular carcinoma","volume":"7","author":"Chen","year":"2024","journal-title":"Commun. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"IMbrave150 investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B8","first-page":"17","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer","volume":"10","year":"2024","journal-title":"Electron. J. Compr. Cancer Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1146693","DOI":"10.3389\/fimmu.2023.1146693","article-title":"Identification of biomarkers co-associated with M1 macrophages, ferroptosis, and cuproptosis in alcoholic hepatitis by bioinformatics and experimental verification","volume":"14","author":"Hou","year":"2023","journal-title":"Front. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.3390\/ijms24087640","article-title":"Predictive biomarkers for immune checkpoint inhibitor treatment response in patients with hepatocellular carcinoma","volume":"24","author":"Ji","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/iub.2804","article-title":"The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer","volume":"76","author":"Jiang","year":"2024","journal-title":"IUBMB Life"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","article-title":"Toward understanding the origin and evolution of cellular organisms","volume":"28","author":"Kanehisa","year":"2019","journal-title":"Protein Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3350\/cmh.2022.0212","article-title":"Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e20200600","DOI":"10.1084\/jem.20200600","article-title":"Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling","volume":"217","author":"Lepelley","year":"2020","journal-title":"J. Exp. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1158\/0008-5472.CAN-13-3485","article-title":"RNA editome imbalance in hepatocellular carcinoma","volume":"74","author":"Qi","year":"2014","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/ijms27041706","article-title":"COPG1 is a selectively essential regulator of cancer progression and chemoresistance via Redox modulation and AKT signaling","volume":"27","author":"Sen","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10916-023-01968-7","article-title":"Radiological diagnosis of chronic liver disease and hepatocellular carcinoma: a review","volume":"47","author":"Singh","year":"2023","journal-title":"J. Med. Syst."},{"key":"B20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jhep.2020.07.021","article-title":"RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis","volume":"74","author":"Song","year":"2021","journal-title":"J. Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/JS9.0000000000001901","article-title":"Antibiotic use attenuates response to immune checkpoint blockade in urothelial carcinoma via inhibiting CD74-MIF\/COPA: revealing cross-talk between anti-bacterial immunity and anti-tumour immunity","volume":"111","author":"Song","year":"2025","journal-title":"Int. J. Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1038\/s41467-022-29946-6","article-title":"Deficiency in coatomer complex I causes aberrant activation of STING signaling","volume":"13","author":"Steiner","year":"2022","journal-title":"Nat. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2018.12.009","article-title":"Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer","volume":"444","author":"Takeda","year":"2019","journal-title":"Cancer Lett."},{"key":"B24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cgh.2022.01.047","article-title":"The performance of AFP, AFP-L3, and DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States","volume":"21","author":"Tayob","year":"2023","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nrgastro.2016.118","article-title":"Gastric cancer: dysregulation of RNA editing in gastric cancer","volume":"13","author":"Thomas","year":"2016","journal-title":"Nat. Rev. Gastroenterology & Hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-024-02985-1","article-title":"S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function","volume":"43","author":"Tu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"215995","DOI":"10.1016\/j.canlet.2022.215995","article-title":"COPA A-to-I RNA editing hijacks endoplasmic reticulum stress to promote metastasis in colorectal cancer","volume":"553","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"217420","DOI":"10.1016\/j.canlet.2024.217420","article-title":"Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth","volume":"611","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat. Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0168-8278(02)00412-9","article-title":"Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate gene overexpression","volume":"38","author":"Wong","year":"2003","journal-title":"J. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41467-017-01658-2","article-title":"Regulation of gene expression and RNA editing in Drosophila adapting to divergent microclimates","volume":"8","author":"Yablonovitch","year":"2017","journal-title":"Nat. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13244-025-01984-w.b","article-title":"Evaluation of a deep-learning segmentation model for patients with colorectal cancer liver metastases (COALA) in the radiological workflow","volume":"16","author":"Zeeuw","year":"2025","journal-title":"Insights Imaging."},{"key":"B33","doi-asserted-by":"publisher","first-page":"33409","DOI":"10.1039\/d2ra06185f","article-title":"A new integrated method for tissue extracellular vesicle enrichment and proteome profiling","volume":"12","author":"Zhang","year":"2022","journal-title":"RSC Adv."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1908605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:21:02Z","timestamp":1787322062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1908605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1908605"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1908605","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1908605"}}